← Back to all trials
Recruiting
NCT05763641
TAD After Chemotherapy in Locally Advanced Breast Cancer
Conditions: Sentinel Lymph Node, Breast Cancer, Locally Advanced
Sex: All
Ages: 18 Years – N/A
Healthy volunteers: No
Enrollment: 162
Sponsor: Hospital Universitari de Bellvitge
Location: Hospital de Bellvitge L'Hospitalet de Llobregat Barcelona
Summary
This is an observational study to validate target axillary dissection (TAD) in locally advanced tumors (cN2 and/or cT4).
Eligibility Criteria
Inclusion Criteria:
* Axillary lymph node metastasis proven by cytology
* Clinical or radiological N2a (at least 4 suspicious lymph nodes on axillary ultrasound at diagnosis)
* Extensive T4 subsidiary to axillary lymphadenectomy according to current clinical criteria
* Neoadjuvant chemotherapy
Exclusion Criteria:
* cN3 verified by imaging tests
* N2 due to internal mammary involvement (N2b).
* Tumors whose surrogate molecular subtype is luminal A.
* Patients undergoing neoadjuvant endocrine therapy
* Patients with local recurrences and metastatic tumors.
Source: ClinicalTrials.gov (NCT05763641). StuddyBuddy aggregates publicly available trial information.
